Additionally, preclinical studies on non-human primates demonstrated PD-1 B-cell peptide cancer vaccination having a similar efficacy than monoclonal anti-PD-1/PD-L1 therapy however with lower rates of adverse side effects [42]. This evidence concerns the gene CD274 and cancer.